SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Micromet Inc (MITI) -- Ignore unavailable to you. Want to Upgrade?


To: Arthur Radley who wrote (90)6/8/2009 4:17:08 PM
From: Biomaven1 Recommendation  Read Replies (1) | Respond to of 196
 
>>Micromet owns 100% of the rights to blinatumomab.

Feuerstein is wrong here. AZN retains an option to get the US rights back, which they would almost certainly exercise if the drug is approved.

Peter